Nrf2: A promising therapeutic target in bone-related diseases - 11/11/23


Abstract |
Nuclear factor erythroid-2-related factor 2 (Nrf2) plays an important role in maintaining cellular homeostasis, as it suppresses cell damage caused by external stimuli by regulating the transcription of intracellular defense-related genes. Accumulating evidence has highlighted the crucial role of reduction-oxidation (REDOX) imbalance in the development of bone-related diseases. Nrf2, a transcription factor linked to nuclear factor-erythrocyte 2, plays a pivotal role in the regulation of oxidative stress and induction of antioxidant defenses. Therefore, further investigation of the mechanism and function of Nrf2 in bone-related diseases is essential. Considerable evidence suggests that increased nuclear transcription of Nrf2 in response to external stimuli promotes the expression of intracellular antioxidant-related genes, which in turn leads to the inhibition of bone remodeling imbalance, improved fracture recovery, reduced occurrence of osteoarthritis, and greater tumor resistance. Certain natural extracts can selectively target Nrf2, potentially offering therapeutic benefits for osteogenic arthropathy. In this article, the biological characteristics of Nrf2 are reviewed, the intricate interplay between Nrf2-regulated REDOX imbalance and bone-related diseases is explored, and the potential preventive and protective effects of natural products targeting Nrf2 in these diseases are elucidated. A comprehensive understanding of the role of Nrf2 in the development of bone-related diseases provides valuable insights into clinical interventions and can facilitate the discovery of novel Nrf2-targeting drugs.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Nrf2 plays an important role in the occurrence and development of bone-related diseases. |
• | Some extracts and drugs target Nrf2 to ease the progression of the bone-related diseases. |
• | Nrf2 may be considered as a potential therapeutic target to combat bone related diseases, especially benign bone diseases. |
Abbreviations : ALS, Alpl, Bglap, ARB, ARE, AU, BTB/POZ, CGRP, COPD, CIA, CBN, CORM, CBSCs, Cul3/Rbx1, COX, cPLA2, CALCR, CTSK, DCSTAMP, DHA, EPA, ESR1, ECM, FLS, HO-1, hBM-MSCs, H2S, HRW, Keap1, KD, KO, LPS, MAFF, MAG, MaR1, MMPs, DMM, MB, MM, NO, Neh, Nrf2, OA, OPG, OVX, PRDX1, PEITC, POMP, ROS, RANKL, RA, Runx2, REDOX, RXRα, SAL, Sp7, spp1, NaB, MIA, SPRC, TRAP, TBHP, β-TrCP, WT
Keywords : Nrf2, Oxidative, Osteoporosis, Facture, Osteoarthritis, Therapeutic target
Plan
Vol 168
Article 115748- décembre 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?